Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 26;110(4):411–419. doi: 10.1093/jnci/djx224

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/about_us/legal/notices)

PMC Copyright notice

Figure 2. — Pathways of cancer therapy on neurocognitive outcomes. Final path models are presented for each neurocognitive measure. All models are adjusted for sex, time since diagnosis, and age at diagnosis. Model fit indices are represented by comparative fit index, Tucker Lewis Index, and root mean square error of approximation. A) The path model for task efficiency. The impact of cranial radiotherapy (RT) on task efficiency is modified by sex (P = .002) and age at diagnosis (P < .001). The impact of anthracyclines on task efficiency is modified by time since diagnosis (P = .03). The impact of thoracic RT on endocrine disease is modified by age at diagnosis (P = .001). The impact of cranial RT on endocrine disease is modified by sex (P = .01), time since diagnosis (P < .001), and age at diagnosis (P < .001). B) Figure 2B shows the path model for memory. The impact of thoracic RT on endocrine disease is modified by age at diagnosis (P = .001). The impact of cranial RT on endocrine disease is modified by sex (P = .003), time since diagnosis (P < .001), and age at diagnosis (P < .001). C) The path model for organization. The impact of thoracic RT on endocrine disease is modified by age at diagnosis (P = .001). The impact of cranial RT on endocrine disease is modified by sex (P = .002), time since diagnosis (P < .001), and age at diagnosis (P < .001). D) The path model for emotional regulation. The impact of anthracyclines on emotional regulation is modified by time since diagnosis (P = .002). The impact of thoracic RT on endocrine disease is modified by age at diagnosis (P = .001). The impact of cranial RT on endocrine disease is modified by sex (P = .004), time since diagnosis (P < .001), and age at diagnosis (P < .001). P values are derived from a probit model with a robust weighted least squares estimator (WLSMV). All P values are two-sided. CFI = comparative fit index; IV = intravenous; RMSEA = root mean square error of approximation; RT = radiation therapy; TLI = Tucker Lewis Index.